Tudor Capital has reduced its short position in medical technology company Raysearch Laboratories
to below 0.5 percent of the capital and is therefore no longer a public short seller in the company.
There are now five public short sellers in the company. In total, 10.6 percent of the capital is shorted in the company.
The Swedish Financial Supervisory Authority requires positions above 0.1 percent to be reported, and short positions above 0.5 percent to be made public.